Generation of partial agonist ligands of the T-cell receptor by engineering of antibodies against CD3.
Chau
L A
LA
John P. Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
Tso
J Y
JY
Madrenas
J
J
D000906:Antibodies / Q000276:immunology*; D017252:CD3 Complex / Q000276:immunology*; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000378:metabolism; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008024:Ligands; D016853:Muromonab-CD3 / Q000276:immunology; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011948:Receptors, Antigen, T-Cell / Q000819:agonists* / Q000276:immunology / Q000378:metabolism; D051746:ZAP-70 Protein-Tyrosine Kinase
D000906:Antibodies; D017252:CD3 Complex; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D008024:Ligands; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell; D011505:Protein-Tyrosine Kinases; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human